Case No. Age/gender Graft Time to PTLD (yr) Location Tumor cell morphology EBV Immunophenotype Molecular results Diagnosis Treatment Outcome
Case 18 60-yr male liver, kidney 0.6 Pleural effusion Plasmablastic Negative HHV8-, CD20-, CD79a-, pax5-, CD30-, cd3-, mum1+, CYTOPLASMIC Lambda restricted MYC-rearranged Monomorphic PTLD with PBL feature Reduced immunosuppressive Died of disease in 2 weeks
Case 229 63-yr male liver 11 Ascites, splenomegaly Plasmablastic Positive PAX5+, MUM1+, CD20-, CD79a-, CD30-, CD45-, HHV8- MYC-rearranged Monomorphic PTLD with PBL feature N/A N/A
Case 331 57-yr male liver 2.0 Pleural effusion Large tumor cells Positive CD20-, CD79a+, kappa restricted, CD3-, CD56-, HHV8- N/A Monomorphic PTLD with PBL feature N/A Died of disease in 3 months
Case 411 12-yr-female heart 10 Small intestine, pleura Plasmablastic Negative CD20-, PAX5-, CD79a+, CD19 partial+, CD138+ MYC-rearranged Monomorphic PTLD with PBL feature Surgery, and chemotherapy In remission at 15-years-followup
Case 511 15-yr-male heart 10 Small intestine Plasmablastic Negative CD20 rare+, CD19+, PAX5+, CD138 partial+, CD79a partial+, HHV8- MYC-rearranged Monomorphic PTLD with PBL feature Chemotherapy (Bortezomib-EPOCH); ASCT In remission at 6-years-followup
Case 614 22-yr-female kidney 17 Small intestine Large tumor cells Negative 1st tumor: CD20+, PAX5+, cytoCD3+, CD30-, CD138-, Ki67>90%, HHV8-, EBV-; 2nd tumor: CD20-, PAX5-, cytoCD3+, CD138+, CD30-, Ki67>90%, HHV8- Polyclonal TCR; Monoclonal IgH 1st tumor: DLBCL; 2nd tumor: PBL, monomorphic PTLD Chemotherapy; ASCT Died of disease in 7 months